pre-filled plastic syringe, kit, use of pre-filled plastic syringe and method for cosmetic skin trea

专利摘要:
The present invention relates to a pre-filled glass container, such as a pre-filled plastic syringe, comprising an aqueous formulation of botulinum toxin. The aqueous formulation of botulinum toxin in the preloaded plastic container is stable for an extended period of time. In addition, the present invention relates to a kit comprising the preloaded plastic container, and the use of the preloaded plastic container for therapeutic and cosmetic purposes.
公开号:BR112017016759B1
申请号:R112017016759-0
申请日:2015-12-22
公开日:2021-01-12
发明作者:Markus Vogt
申请人:Merz Pharma Gmbh & Co. Kgaa；
IPC主号:

专利说明:

FIELD OF THE INVENTION
[0001] The present invention relates to a pre-filled plastic container, such as a pre-filled plastic syringe, comprising an aqueous formulation of botulinum toxin. The aqueous formulation of botulinum toxin in the preloaded plastic container is stable for an extended period of time. In addition, the present invention relates to a kit comprising the preloaded plastic container, and the use of the preloaded plastic container for therapeutic and cosmetic purposes. BACKGROUND OF THE INVENTION
[0002] Botulinum toxin (BoNT) is one of the most potent toxins known and acts by blocking the release of acetylcholine in peripheral cholinergic neurons. BoNT is synthesized as a 150 kDa precursor neurotoxic polypeptide and is activated by selective proteolytic cleavage to produce the two-chain BoNT active form consisting of a 100 kDa heavy chain (HC, includes the translocation domain and the binding domain receptor) and a 50 kDa light chain (LC, includes the catalytic domain) linked by a disulfide bond and non-covalent interactions. There are eight homologous serotypes (A, B, C1, C2, D, E, F and G) of botulinum toxin, which are produced by the bacterium Clostridium botulinum in the form of a complex consisting of a neurotoxic polypeptide and other (non-toxic) clostridial proteins (ie different hemagglutinins and a non-toxic, non-hemagglutinating protein).
[0003] Careful administration of very small doses of toxin can restrict its action locally to reduce hyperactive muscles and exocrine glands. Therefore, botulinum toxin is now used in the treatment of a wide range of debilitating neuromuscular diseases (eg, cervical dystonia, blepharospasm and spasticity), hyperactive exocrine glands (eg, hyperhidrosis and hypersalivation) and other diseases, as well as for aesthetic purposes (for example, facial wrinkle treatment).
[0004] Botulinum toxins are inherently unstable and, in particular, are known to be highly unstable at alkaline pH and thermolabile. In addition, it is known that diluting the isolated toxin complex from milligram quantities to much lower toxin concentrations used in injection solutions (in the range of nanograms per milliliter) presents significant difficulties due to the rapid loss of specific activity after such a great dilution. This causes a loss of biological activity during the production, reconstitution and / or storage of pharmaceutical compositions containing protein. These problems observed with proteins may be due to chemical instability, which results in the formation or cleavage of bonds (for example, hydrolysis, oxidation, racemization, β-elimination and disulfide exchange), and / or due to the physical instability of the protein structure second order or higher order, without modification of covalent bond break (for example, denaturation, adsorption to surfaces and non-covalent self-aggregation).
[0005] The stability of pharmaceutical products is therefore of paramount importance to ensure safe and effective use for a sufficiently long period of time. Since aqueous botulinum toxin formulations are particularly prone to degradation, commercial botulinum toxin preparations often come as vacuum-dried or lyophilized material. Examples include, for example, Botox® (onabotulinumtoxinA, Allergan, Inc.) and Dysport® (abobotulinumtoxinA; Ipsen Ltd.), both of which contain the toxin complex C. botulinum type A. Another example is Xeomin® (incobotulinumtoxin , Merz Pharma GmbH & Co. KGaA), which contains the pure neurotoxic component of serotype A (ie the 150 kDa neurotoxic polypeptide) and is devoid of any other proteins from the toxin complex Clostridium botulinum (ie the different hemagglutinins and non-toxic, non-hemagglutinating protein).
[0006] However, although the lyophilized material has increased stability, it should generally be reconstituted with a pharmaceutically acceptable liquid (eg, saline) before use. Lyophilized pharmaceutical products are therefore considered less convenient than other dosage forms. In addition, the reconstitution process carries the risk of maladministration, resulting in inaccurate dosing or sterility problems. In addition, the lyophilization process is time consuming and results in additional costs.
[0007] Another disadvantage of reconstituted botulinum toxin solutions is that they are generally not used entirely because not all patients and indications require the same dosage. Unfortunately, due to its instability, the reconstituted toxin solution can only be stored and reused for a relatively short period. For example, after dilution with normal saline before use, it is recommended to use Botox® and Dysport® within 6 hours and 4 hours, respectively. Likewise, the Xeomin® packaging leaflet specifies that, after storage for more than 24 hours, the reconstituted Xeomin® solution should no longer be used.
[0008] One medical dosage form that overcomes most of these disadvantages is the shape of the pre-filled syringe, which has found increasing acceptance in recent years as a drug delivery device. However, if proteins are used as active ingredients, the protein's limited stability often makes it particularly difficult for scientists to formulate them for use in a pre-filled syringe format. In particular, this applies to very dilute aqueous solutions of botulinum toxin.
[0009] In order to increase the stability of solid or liquid pharmaceutical botulinum toxin compositions, stabilizing proteins such as human serum albumin (HSA) are often added. In addition, it is known to add non-proteinaceous stabilizing agents, such as surfactants, polyvinylpyrrolidone (PVP), disaccharides, polyols and the like. However, the stability of liquid botulinum toxin formulations is still unsatisfactory and / or is achieved using substances undesirable for human use by injection (see, for example WO 01/58472, WO 2006/005910 and WO 2007/041664).
[0010] In addition, WO 00/15245 discloses a highly concentrated liquid formulation of botulinum toxin type B (about 2,500 U / ml) that is stable when stored in glass vials at 5 ° C for up to 30 months. However, this stability is only achieved with the use of vials made of glass and buffering the pH of the solution to an acidic pH between 5 and 6, which causes pain after injection.
[0011] Despite advances in technique, there is still no presentation of injectable botulinum toxin that is stable not only for a long period to provide a sufficiently long life, but that is also convenient and easy to use, reduce medication errors and minimize the risk of contamination. OBJECTIVE OF THE INVENTION
[0012] In view of the above, the aim of the present invention is to provide a stable medical dosage form for the administration of botulinum toxin in a convenient, safe and simple manner. SUMMARY OF THE INVENTION
[0013] The objective above is solved by the provision of a pre-filled plastic container of botulinum toxin (for example, a syringe, vial, cartridge or ampoule). The liquid formulation of botulinum toxin in the pre-filled plastic container (for example, a syringe, vial, cartridge or ampoule) is stable at 2 to 8 ° C for an extended period of time to provide a sufficiently long life (at least about 12 to 24 months).
[0014] In a first aspect, the present invention provides a pre-filled plastic container (for example, a syringe, vial, cartridge or ampoule) that comprises an aqueous formulation of botulinum toxin, in which the activity of the toxin is not reduced more than 25% in relation to the initial activity of the toxin, after storage of the pre-loaded container for (a) 12 months at 5 ° C or (b) 3 months at 25 ° C.
[0015] The stability of the aqueous botulinum toxin formulation in the pre-filled container (for example, a syringe, vial, cartridge or ampoule) in terms of the count (number) of subvisible particles equal to or greater than 10 μm is also excellent and, generally below 1,000 / mL during storage for 6 to 24 months (for example, 6, 9, 12, 15, 18 or 24 months) at 2 to 25 ° C (for example, at 5 ° C or 25 ° C ). In addition, the aqueous formulation of botulinum toxin in the pre-loaded container has excellent pH stability, as indicated by a pH value that generally does not increase or decrease by more than 10% compared to the initial pH value, during the storage of the pre-filled container (for example, a syringe, vial, cartridge or ampoule) for 6 to 24 months (for example, 6, 9, 12, 15, 18 or 24 months) at 2 to 25 ° C (for example , at 5 ° C or 25 ° C).
[0016] In another aspect, the present invention provides a kit comprising a pre-loaded plastic container (for example, a syringe, vial, cartridge or ampoule), according to the first aspect of the invention and, optionally, instructions of using said pre-loaded plastic container.
[0017] In a further aspect, the present invention provides a pre-filled plastic container (for example, a syringe, vial, cartridge or ampoule), according to the first aspect of the invention, for use in therapy. For example, the preloaded plastic container (for example, a syringe, vial, cartridge or ampoule) can be used to treat a disease or condition caused by or associated with the overactive cholinergic innervation of muscles or exocrine glands in a patient, including, but not limited to, dystonia, spasticity, paratonia, dyskinesia, focal spasm, strabismus, tremor, tics, migraine, sialorrhea and hyperhidrosis.
[0018] In yet another aspect, the present invention relates to the use of the pre-loaded plastic container (for example, a syringe, vial, cartridge or ampoule) according to the first aspect of the invention in cosmetic applications, such as for the treatment of skin wrinkles and facial asymmetries, for example, expression lines in the glabellar region, crow's feet, upper facial rhythms and platysma bands.
[0019] In still a further aspect, the present invention provides a method for the treatment of a disease or condition caused by or associated with the overactive cholinergic innervation of the muscles or exocrine glands in a patient, the method comprising administering locally a quantity efficacy of botulinum toxin to a muscle or exocrine gland of the patient by injection using the pre-filled plastic container (e.g., a syringe, vial, cartridge or ampoule) according to the first aspect of the invention.
[0020] In yet an additional aspect, the present invention relates to a method for the cosmetic treatment of the skin, such as for the treatment of skin wrinkles and facial asymmetries, the method comprising administering locally an effective amount of botulinum toxin to a patient by intradermal, subdermal or subcutaneous injection, using the pre-filled plastic container (for example, a syringe, vial, cartridge or ampoule) according to the first aspect of the present invention.
[0021] Additional modalities of the present invention are defined in the attached dependent claims. The present invention can be more fully understood by reference to the following detailed description of the invention, the examples and the accompanying drawings. BRIEF DESCRIPTION OF THE FIGURES
[0022] Figure 1 shows the stability of a liquid botulinum toxin formulation in pre-filled syringe configurations A (•) and B (o) at 5 ° C as a function of time. DETAILED DESCRIPTION OF THE INVENTION
[0023] The present invention is based on the unexpected discovery that a liquid formulation of botulinum toxin in a plastic container (for example, in the form of a syringe, vial, cartridge or ampoule) shows excellent long-term stability under reduced temperatures (for example, 2 to 8 ° C). Even under storage at room temperature (eg 25 ° C), the pre-loaded container of botulinum toxin has surprisingly high stability.
Consequently, the pre-filled liquid botulinum toxin formulation container of the present invention, in particular the pre-filled botulinum toxin syringe of the present invention, not only has a sufficiently long life (at least about 12 to 24 months), but it has several additional advantages compared to other forms of administration, such as easy and convenient use, reduced risk of medication errors, high dosage accuracy, low risk of contamination, guarantee of increased sterility and / or high degree of administration security.
[0025] In addition, the use of plastic materials for containers (for example, syringes) offers advantages over glass containers (for example, glass syringes) in terms of breaking strength, weight reduction, greater flexibility for new shapes primary containers, improved dimensional tolerances and absence of undesirable substances (eg adhesives).
[0026] Plastic materials contain various substances and additives (eg plasticizers) commonly known as leachables / extractables that are known to easily destabilize proteins, particularly if they are fragile in nature and / or used in low concentrations as neurotoxins (for example, botulinum toxin). Therefore, liquid liquid neurotoxin formulations are conventionally injected using glass syringes. Surprisingly, however, it has been found that the pre-loaded plastic container (e.g., syringe) according to the present invention provides stability to an aqueous formulation of botulinum toxin over a long period of storage (at least about 12 to 24 months) at 2 to 8 ° C and thus provides a sufficiently long life.
[0027] As used herein, a "pre-loaded container" refers to any device with a fully or partially enclosed space that can be sealed or sealed, and that can be used to contain, store and / or transport liquid formulations. A "pre-loaded container" within the meaning of the present invention is preferably a closed (or sealed) container made of, or partially or predominantly, made of plastic (for example, organic polymers) and includes, for example, containers under in the form of (i) a syringe, (ii) a vial, (iii) a cartridge or (iv) an ampoule.
[0028] The pre-filled cartridges and syringes have two openings that are sealed to prevent leakage of the contents (for example, aqueous formulations). In the case of a pre-filled syringe, the proximal end is sealed by a plunger stopper, and the distal end is sealed by a cap device, as explained in detail here below. In the case of a plastic cartridge, which is generally a sterile plastic cylinder filled with a drug formulation, the proximal end is typically sealed by a rubber stopper. This rubber stopper can be pressed like a piston into the cylinder by pressing a puncture on the cartridge syringe. The distal end is typically sealed by a puncture membrane. The puncture membrane is perforated for injection.
[0029] A "vial" within the meaning of the present invention is a vessel that normally has a tubular shape or a bottle shape with a neck and that is suitable for containing, storing and / or carrying drug formulations. The single opening is capable of being sealed by different bottle closure systems. For example, the bottles can be closed with a screw cap (screwed bottles), a cork, plastic or rubber stopper ("lip bottles" (closed with a cork or plastic stopper) and "crimp bottles" (closed with a stopper) rubber and metal cap) and other closure systems, such as flip-top or snap-on caps. In the context of the present invention, a "bottle" preferably means a plastic bottle with its opening sealed with a locking system. bottle closure.
[0030] In the following, the present invention is described in more detail. It should be noted that although the term "pre-filled syringe", "pre-filled plastic syringe", "syringe" or "plastic syringe" is used in the detailed description of the invention, this does not mean that it is limited to a (plastic) syringe as a specific embodiment of the (plastic) container. In fact, any reference in the present invention to a "pre-filled syringe", "pre-filled plastic syringe", "syringe", "plastic syringe" or the like should be understood as a reference to, and the disclosure of, a "container" or "plastic container", and also includes, or discloses, a "plastic bottle" or "bottle", a "plastic cartridge" or "cartridge", or a "plastic ampoule" or "ampoule" "unless otherwise stated.
[0031] In a first aspect, the present invention relates to a pre-filled plastic syringe comprising botulinum toxin in an aqueous formulation, in which the activity of the toxin is not reduced by more than 25% in relation to the initial activity of the toxin , after storing the pre-filled syringe for (a) 12 months in standard refrigerator temperatures (ie 2 to 8 ° C, such as 5 ° C), or (b) 3 months at 25 ° C. Preferably, the activity of the toxin is not reduced by more than 20%, 15%, 10% or 5%, compared to the initial activity of the toxin, after storage of the pre-filled syringe for 12 months at 2 to 8 ° C (eg 5 ° C) or is not reduced by more than 20%, relative to the initial activity of the toxin, after storage of the pre-filled syringe for 3 months at 25 ° C. More preferably, the activity of the toxin is not reduced by more than 15%, 10% or 5%, compared to the initial activity of the toxin, after storage of the pre-filled syringe for 6 months at 2 to 8 ° C (for example , 5 ° C).
[0032] Surprisingly, the aqueous formulation of botulinum toxin in the pre-filled syringe is also stable for even longer periods of storage, up to 24 months. For example, after storage for up to 24 months (for example, 15, 18 or 24 months) at 2 to 8 ° C (for example, 5 ° C), the activity of the toxin is preferably not reduced by more than 30% or 25%, more preferably, by not more than 20%, in particular, by not more than 15%, particularly preferably by not more than 10% and, more preferably, by not more than 5% in relation to the initial activity of toxin.
[0033] Within the present invention, the term "toxin potency" refers broadly to a measure of drug activity (e.g., botulinum toxin) expressed in terms of the amount needed to produce an effect of a certain intensity. The term "activity" or "toxin activity", as used herein, refers to the biological activity of botulinum toxin, where "biological activity" can refer to (a) receptor binding, (b) internalization, (c) translocation through the endosomal membrane in the cytosol and / or (d) endoproteolytic cleavage of the proteins involved in the fusion of the synaptic vesicle membrane. For example, any light chain (LC) domain, which shows proteolytic activity of more than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and up to 100% the corresponding wild-type LC domain in an SNAP-25 assay can be considered "biological active" or "exhibiting proteolytic activity" within the scope of the present invention. In addition, any heavy chain (HC) domain that is capable of binding to a cellular receptor of the HC domain, in particular to its native HC domain receptor, and is capable of translocating an LC domain bound to it, is considered " biologically active ".
[0034] Biological activity is commonly expressed in mouse units (MU). As used here, 1 MU is the amount of neurotoxic component that kills 50% of a specified mouse population after intraperitoneal injection, that is, LD50 ip, as measured according to the method of Schantz and Kauter (Schantz and Kauter, J. Assoc. Off. Anal. Chem. 1978, 61: 96-99). In this document, the terms "MU" and "Unit" or "U" are used interchangeably.
[0035] Suitable assays to assess biological potency or activity include the mouse hemidiaphragm (MHA) assay described by Pearce et al. (Toxicol. (Toxicol. Appl. Pharmacol. 128: 69 to 77, 1994) and Goschel et al. (Exp. Neurol. 147: 96 to 110, 1997), the mouse diaphragm assay (MDA) according to Dressler et al. (Mov. Disord. 20: 1617-1619, 2005), an SNAP-25 protease assay (for example, the "GFP-SNAP25 fluorescence release assay" described in WO 2006/020748 or the "improved SNAP25 immuno-assay endopeptidase "described in Jones et al., J. Immunol. Methods 329: 92-101, 2008), the electrochemiluminescence sandwich (ECL) ELISA described in WO 2009/114748 and cell-based assays, such as those described in WO 2009/114748, WO 2004/029576, WO 2013/049508 and in WO 2014/207109.
[0036] As used in the present invention, the term "initial toxin activity" or "initial toxin potency" generally refers to the activity of botulinum toxin at the beginning of the storage period, that is, after the manufacture of the pre-filled syringe with final botulinum toxin, for example, a week or less after manufacture. In addition, the term "after storage" in the present invention means after or at the end of storage for a given period of time. In addition, the term "during storage" generally means throughout the storage period.
[0037] In addition to a high stability in terms of toxin potency, the aqueous formulation of botulinum toxin is also highly stable in terms of subvisible particle count. A "subvisible particle" within the meaning of the present invention is typically a particle with a diameter of less than 100 µm. According to the present invention, the sub-visible particle count, more specifically the count (or number) of particles equal to or greater than 10 μm in the aqueous botulinum toxin formulation is typically below 1,000 / mL, preferably below 600 / mL and, more preferably, below 200 / mL during storage for 6 to 24 months (for example, 6, 9, 12, 15, 18 or 24 months) at 2 to 25 ° C (for example, 5 ° C or 25 ° C).
[0038] Measurements of the number of particles can be performed by different methods, such as flow microscopy imaging (MFI), resonant mass measurement (RMM) and nanoparticle tracking analysis (NTA). Particle measurements normally take place according to USP <788>. In the context of the present invention, the flow microscopy imaging method is preferably used. This measurement method can, for example, be performed using a DPA-5200 particle analyzer system (ProteinSimple, Santa Clara, CA, USA) equipped with a high-resolution 100 μm flow cell coated with silane. Generally, samples are analyzed undiluted.
[0039] Alternatively, resonant mass measurements (RMM) can be performed to determine the number of particles using, for example, the Archimedes particle metrology system (Affinity Biosensors, Santa Barbara, CA, USA) equipped with a microsensor (size range from 0.3 to 4 μm) calibrated with polystyrene standards of 1 μm. Normally, all samples are analyzed without dilution. The results can be analyzed using ParticleLab software (v1.8.570) with a compartment step size of 10 nm. As another alternative to determine the number of particles, nanoparticle tracking analysis (NTA) can be used, for example, with the use of a NanoSight LM20 system (NanoSight, Amesbury, United Kingdom). Samples are normally measured undiluted. The particle movements in the samples can be recorded as 60-second videos at room temperature and analyzed using appropriate software (for example, NTA 2.3 Software).
[0040] In addition, the aqueous formulation of botulinum toxin has high pH stability, since the pH value is essentially stable during the storage of the pre-filled syringe. Preferably, the pH value does not increase or decrease by more than 10%, 8% or 6% in relation to the initial pH value after storage of the pre-filled syringe for 6 to 24 months (eg 6, 9, 12, 15, 18 or 24 months) at 2 to 25 ° C (for example, at 5 ° C or 25 ° C), for example, for 18 months at 25 ° C or 24 months at 25 ° C. The pH can be measured according to the American Pharmacopoeia USP <791> standardized test method, which describes pH measurements for a multitude of pharmaceutical products. Any suitable pH meter can be used, for example the pH meter Lab 870, from Schott Instruments.
[0041] As used here, the term "pre-filled syringe" refers to a syringe that is filled with a drug composition (ie, an aqueous formulation of botulinum toxin) prior to distribution to the end user, who will administer the drug to the patient. The term "aqueous formulation", as used herein, is intended to refer to an aqueous solution, suspension, dispersion or emulsion, and preferably refers to an aqueous solution. In general, a pre-filled syringe includes a drug containment container that forms part of a syringe body (i.e. a syringe barrel), a plunger to seal the proximal opening of the syringe and to expel the drug and a device seal (for example, a tip cap or needle guard) at the syringe outlet end (for example, the open end of the syringe tip or a pre-assembled needle (cannula) to seal the outlet opening distal. The term "pre-filled plastic syringe", within the meaning of the present invention, refers to a pre-filled syringe, of which at least the cylinder is made of plastic.
[0042] In the context of the present invention, the pre-filled syringe is preferably a luer slip or luer lock syringe equipped with a tip cap (if no needle is pre-assembled) or a needle protector (if the needle pre-assembled). For the purposes of the present invention, a "luer slip syringe" is a syringe that allows a needle to be pushed into the tip tip, while a "luer-lock syringe" is a syringe that allows a needle to be twisted over the tip and then locked in place. This provides a secure connection and prevents accidental removal of fluid injection needles.
[0043] The pre-filled plastic syringe according to the present invention is generally sterilized (for example, by gamma radiation, treatment with ethylene oxide (ETO) and moist heat (for example, autoclave)). Sterilization can be carried out before aseptic filling with the aqueous botulinum toxin formulation or after filling with the aqueous botulinum toxin formulation. The final pre-filled plastic syringe is ready for use. In addition, the pre-filled syringe described herein is generally intended for single use and is designed to be disposable. Prior to sterilization, the inner surface of the plastic syringe cylinder is typically coated with a lubricant to facilitate sliding of the plunger stopper and expelling the contents of the syringe.
[0044] According to the present invention, the aqueous formulation of botulinum toxin in the pre-filled plastic syringe contains the botulinum toxin in a concentration of, for example, 1 U / ml to 3,000 U / ml, or 10 U / ml at 1,000 U / mL. Preferably, the botulinum toxin is present in a concentration of about 10 U / ml to 400 U / ml, more preferably, from about 25 U / ml to 200 U / ml and more preferably, from about 40 U / ml to 150 U / ml (e.g. 50 U / ml, 75 U / ml or 100 U / ml).
[0045] The term "botulinum toxin", as used here, refers widely to any form or type of botulinum toxin. More specifically, botulinum toxin can be selected from botulinum toxin types A, B, C1, C2, D, E, F or G, or mixtures thereof. Preferably, the botulinum toxin is serotype A, B or C1, particularly serotype A.
[0046] In addition, the term "botulinum toxin" is intended to include both the botulinum toxin complex (the "toxin complex") and the "neurotoxic component" of a botulinum toxin (complex). As used in the present invention, the term "botulinum toxin complex" or "toxin complex" refers to a high molecular weight complex, which comprises the neurotoxic component of approximately 150 KDa and, in addition, non-toxic proteins of Clostridium botulinum , including hemagglutinin and non-hemagglutinin proteins. The botulinum toxin serotype A complex is commercially available, for example, as Botox® (Allergan, Inc.) or as Dysport® (Ipsen, Ltd.).
[0047] The term "neurotoxic component", as used here, refers to the neurotoxic polypeptide of the toxin complex (the "150 kDa" polypeptide; usually in its two-chain form) without any associated non-toxic proteins. The pure neurotoxic component is, for example, commercially available under the trade names Xeomin® and Bocouture® (Merz Pharmaceuticals GmbH). Preferably, the term "botulinum toxin" means the neurotoxic component of a botulinum toxin complex of a given serotype (e.g., serotype A, B or C1, particularly serotype A). In other words, the aqueous formulation of botulinum toxin contained in the pre-filled plastic syringe preferably (only) contains said neurotoxic component and is devoid of any other proteins of the Clostridium botulinum toxin complex.
[0048] It is also contemplated that the present invention comprises isoforms, homologs, orthologs, functional fragments and fragments of botulinum toxin (ie biologically active) that show at least 50%, at least 60%, at least 70%, at least 80 %, at least 90% and up to 60%, up to 70%, up to 80%, up to 90% or up to 99% sequence identity with the amino acid sequence of wild type botulinum toxin, such as wild type botulinum toxin A or neurotoxic component of botulinum toxin of serotype A1 deposited in the GenBank database under accession number AAA23262. The sequence identity can be calculated by any suitable algorithm to produce reliable results, for example, using the FASTA algorithm (W.R. Pearson & D.J. Lipman, PNAS 85: 2444 to 2448, 1988). The sequence identity can be calculated by comparing two polypeptides or two domains, such as two LC domains or fragments thereof.
[0049] Modified and recombinant botulinum toxins are also within the scope of the present invention. Regarding suitable mutants, reference is made to documents WO 2006/027207, WO 2009/015840, WO 2006/114308, WO 2007/104567, WO 2010/022979, WO 2011/000929 and WO 2013/068476, which are all incorporated by reference to the present invention. In addition, the present invention also relates to botulinum toxins, which are chemically modified, for example, by pegylation, glycosylation, sulfation, phosphorylation or any other modification, particularly of one or more amino acid (s) exposed on the surface or in the solvent. The modified and recombinant isoforms, homologs, orthologs, fragments and mutants and mutants suitable for use in the present invention are biologically active, that is, capable of and translocating in the cytosol of presynaptic cholinergic neurons to cleave the SNARE complex proteins (for example, VAMP / syntaxin, synaptobrevine and SNAP-25) to exert their inhibitory effects on acetylcholine.
[0050] In the context of the present invention, the aqueous formulation of botulinum toxin may comprise several other pharmaceutically acceptable substances, for example, salts (for example, sodium chloride), stabilizing proteins (for example, albumin, gelatin), sugars (for example, glucose, fructose, galactose, trehalose, sucrose and maltose), carbohydrate polymers (e.g., hyaluronic acid and polyvinylpyrrolidone (PVP)), polyols (e.g., glycerol and sugar alcohols such as mannitol, inositol, lacttlol, isomalt, xylitol, erythritol, sorbitol), amino acids, vitamins (for example, vitamin C), zinc, magnesium, anesthetic agents (for example, local anesthetic agents such as lidocaine), surfactants, tonicity modifiers and the like. The term "pharmaceutically acceptable", as used herein, refers to those compounds or substances that are suitable for contact with mammalian tissues, especially humans.
[0051] Furthermore, the term "comprises", as used herein, is intended to cover both the non-limited term "includes" and the limited term "consists (of)". The term "produced from", as used here, is intended to refer broadly to "produced from / from", in particular, mainly produced from, and generally means "comprising" (indicating that other substances or materials may be included in some quantities). It can also mean "consisting of".
[0052] According to the present invention, the pH of the aqueous botulinum toxin formulation in the pre-filled syringe during storage is preferably in the range of 6.0 to 7.5, 6.5 to 7.5, 6.1 to 7.3 or 6.2 to 7.2, with more preference in the range of 6.3 to 7.1, and with the most preference in the range of 6.5 to 7.0. A pH within the indicated range of 6.1 to 7.3 is advantageous, as injections of such neutral or only slightly acidic solutions are much less painful after injection than acidic solutions with a pH below 6.
[0053] The term "aqueous formulation" or "aqueous formulation of botulinum toxin", as used herein, is not particularly limited and may refer to an aqueous suspension, aqueous dispersion, aqueous emulsion and, preferably, an aqueous solution.
[0054] Preferably, the aqueous botulinum toxin formulation preferably does not contain a buffer, such as a phosphate buffer, a phosphate-citrate buffer, a lactate buffer, an acetate buffer and the like. The term "buffer", as used herein, denotes a pharmaceutically acceptable excipient, which stabilizes the pH of a pharmaceutical preparation. In addition, the aqueous formulation of botulinum toxin may be free of amino acids (eg, methionine) and / or surfactants (eg, polysorbates, such as polysorbate 80) and / or proteins of animal origin (eg, human serum albumin) (HSA) or bovine serum albumin (BSA)).
[0055] A preferred aqueous formulation of botulinum toxin for use in this document comprises water, botulinum toxin (for example, the neurotoxic component of botulinum toxin, preferably serotype A) at a concentration of, for example, 10 to 150 U / mL, a salt (for example, sodium chloride) in a concentration of, for example, 0.5% to 1.5% w / v, a sugar (for example, a mono or disaccharide, such as glucose, fructose, galactose , trehalose, sucrose and maltose) in a concentration of, for example, 0.1% to 2% w / v, and a stabilizing protein (for example, albumin) in a concentration of less than 4%, 3%, 2 % or 1% w / v, for example 0.01% to 1% w / v.
[0056] A particularly preferred aqueous botulinum formulation for use in the present invention consists essentially of water, botulinum toxin (for example, the neurotoxic botulinum type A component), sodium chloride, sucrose and albumin (for example, human serum albumin, HSA ). The concentration of the mentioned ingredients can be in the following ranges: 10 to 200 U / mL, preferably 30 to 125 U / mL (botulinum toxin), 0.5% to 1.5% w / v, preferably 0.7% at 1.1% w / v (sodium chloride), 0.1% at 2% w / v, preferably 0.2% at 1% w / v (sucrose), 0.01% at 1% w / v, preferably 0.05% to 0.5% w / v (HSA). Another particularly preferred formulation of botulinum toxin for use in the present invention is a solution of Xeomin®, for example, a solution of Xeomin® reconstituted with saline (sodium chloride 0.9%), containing 20 to 150 U / ml of neurotoxic component of botulinum toxin type A.
[0057] The term "essentially consists of", as used in the present invention, means that substances other than those indicated are contained only in trace amounts, for example, unavoidable impurities contained in the components used to formulate the aqueous formulation of botulinum toxin, or impurities included in the isolated botulinum toxin (for example, the neurotoxic component of botulinum toxin type A) in very low amounts as a result of the purification procedure (for example, very low residual amounts of buffers, chelating agents and the like).
[0058] According to the present invention, the configuration of the pre-filled plastic syringe is not particularly limited and generally comprises a fluid receiving cylinder which, after filling, is removably capped by a cap device to close in order sealable, the distal end of the syringe (for example, by a "tip cap" that is removed and replaced with a needle before use, or a sealing means such as a needle guard in the case of a pre-filled syringe with a removable or permanent needle) and is closed at the proximal end by its plunger or any other means that is in tight connection with the cylinder's internal wall. To use the pre-filled syringe, the tip cap, needle guard or other type of cap device are optionally removed, a needle is attached (if not already present) and the plunger or piston tip advances into the cylinder to inject the contents (ie, the aqueous botulinum toxin formulation) of the cylinder into a patient.
[0059] The pre-filled plastic syringe according to the present invention preferably comprises: (86) a plastic syringe cylinder, which includes a proximal end and a distal end, and a generally cylindrical wall that extends between them and defines a cylinder lumen, the syringe cylinder has a tip that protrudes distally with a fluid passage that extends through it and communicates with the cylinder lumen, the generally cylindrical wall having a surface inside optionally coated with a barrier layer, (87) a cap device with a portion that interconnects with the outlet, that connects in a sealable way and closes the end of the open distal outlet of the syringe, the portion that connects the outlet is made of an elastomeric material which optionally has a coating on its surface, and (88) a piston rod assembly that extends to the proximal end of the cylinder eringa and includes a plunger stopper in a sliding watertight engagement with the cylindrical wall of the cylinder lumen, the plunger stopper being made of an elastomeric material that optionally has a coating on at least a portion of the entering plunger stopper in contact with the aqueous botulinum toxin formulation during storage and / or injection.
[0060] The materials in the pre-filled syringe that have the potential to interact with the aqueous formulation of botulinum toxin in the pre-filled syringe are generally selected to minimize or limit the amount of extractables and leachables, since extractables / leachables have the potential to contaminate the aqueous formulation of botulinum toxin and impair the stability, for example, in terms of potency or biological activity, of botulinum toxin.
[0061] As used here, the terms "extractable / extractable" and "leachable / leachable" refer to chemical species that can be released from a container or material component of the pre-filled plastic syringe and / or that have migrated from the materials syringe for the aqueous formulation of botulinum toxin under normal conditions of use or storage. Methods for identifying extractables / leachables are known in the art and based on industry best practices and International Conference for Harmonization (ICH) guidelines (see, for example, FDA guidance, Container Closure Systems for Packaging Human Drugs and Biologics ). Exemplary methods include, for example, liquid chromatography / mass spectrophotometry (LC / MS), gas chromatography spectroscopy / mass spectrophotometry (GC / MS), inductively coupled plasma (ICP) and infrared (IR).
[0062] In the context of the present invention, the inner surface of the plastic cylinder may be coated or may not be coated. However, it is usually coated with a barrier layer for lubrication purposes (hereinafter also called a "lubricant layer"). The lubricant layer must provide not only a high degree of lubricity, allowing the plunger to slide easily through the cylinder, but also be compatible with the aqueous formulation of botulinum toxin and protect its life. In the context of the present invention, the lubricant layer can be a silicone-free lubricant layer or a silicone lubricant layer.
[0063] Likewise, the inner surface of the plastic part of the vial, the inner surface of the plastic cylinder of the cartridge and the inner surface of the plastic ampoule can optionally be coated with a barrier layer and, in particular, with a silicone-free layer or with a silicone layer. Thus, all comments provided below regarding the silicone-free lubricant layer and the silicone lubricant layer of the plastic syringe apply equally to the silicone-free layer and the silicone layer, respectively, of the plastic bottle, the plastic and the plastic ampoule.
[0064] Suitable silicone-free fluoropolymer lubrication layers can be made from the materials described below for the optionally present coatings of the cover device (or more specifically of the outlet hitch portion) and the plunger stopper. Preferred silicone-free lubrication layers include fluoropolymer (fluorocarbon) layers, in particular ethylene-tetrafluoroethylene (ETFE) layers and perfluoropolyether-based layers (based on PFPE) (eg TriboGlide®), as well as coatings of glass based on silicon oxide PECVD (plasma vapor deposition intensified by plasma).
[0065] Such fluoropolymer layers can be prepared as is known in the art, for example, by spraying plastic syringe cylinders with perfluoropolyether oil to obtain a thin layer of lubricant inside the syringe surface, followed by exposing the internal cavities to a plasma of inert gas downstream (for example, argon or helium). Plasma treatment leads to crosslinking of the perfluoropolyether, thereby immobilizing the coating and reducing its tendency to migrate off the target surface, resulting in fewer particles that potentially impair the stability / efficacy of the botulinum toxin drug. An exemplary production process is described in WO 2014/014641 A1, the content of which is incorporated herein by reference. In addition, a silicone-free barrier coating particularly suitable for use in the present invention is known in the art as TriboGlide® coating, a cross-linked perfluoropolyether coating by plasma treatment.
[0066] A silicone lubricant layer suitable for use in the present invention can be prepared by a siliconization method selected from, but not limited to, silicone oil based methods (for example, spray siliconization ( spray-on or baked-on siliconization and vapor deposition methods (eg plasma-enhanced chemical vapor deposition (PECVD)). Preferably, the silicone lubricant layer is formed by spray siliconization or, more preferably, by siliconization by cooking.
[0067] In the spray siliconization method, a silicone oil (eg DOW CORNING® 360 with a viscosity of 1,000 mm2 / s (1,000 cSt)) is sprayed into the syringe (ie into the cylinder) using of, for example, a dip or static nozzle to produce a thin layer of silicone oil. Although silicone oil is an excellent lubricant, excess silicone oil can lead to the formation of unwanted visual and subvisual silicone oil particles. With protein-based drugs, in particular, these silicone oil particles can cause undesirable interactions with protein drugs. For example, sub-visual silicone oil particles are thought to promote protein aggregation. Therefore, since this results in fewer sub-visual and visual silicone oil particles, siliconization processes by cooking are particularly preferred for use in the present invention. This involves applying silicone oil as an emulsion (for example, the DOW CORNING® 365 siliconizing emulsion), which is then baked on the plastic surface at a specific temperature and for a specific period of time.
[0068] The design of the plastic syringe cylinder is not particularly limited and typically has an internal diameter adjusted to accommodate the desired fill volume, for example, 0.5 cm3, 1.0 cm3, 1.5 cm3 or 2 , 0 cm3. Generally, the syringe cylinder has graduated marks that indicate the volume of liquid in the syringe. In addition, the syringe barrel may include an interface such as a flange. The flange design, for example, can be ISO11040 compliant. The interface as a flange can also be compatible with an optionally present cable.
[0069] The tip of the syringe is usually integrally formed (for example, molded) with the plastic barrel of the syringe. Preferably, the syringe barrel includes an integrally formed luer lock tip or an integrally formed luer slip tip. The tip is formed with an integral passage that extends axially through the tip and is in communication with the chamber to dispense the contents of the syringe cylinder. The tip may have a substantially frusto-conical shape that converges from the distal outlet end of the syringe cylinder towards the tip outlet end. Alternatively, the tip can be characterized as divergent (that is, expanding from a smaller diameter to a larger diameter). In addition, the tip is usually located centrally in relation to the syringe body (concentric syringe tip), but it can also be located offset towards the edge of the body (eccentric syringe tip).
[0070] With respect to the plastic cylinder material of the syringe, the plastic material is preferably an olefin cycle polymer (COP), an olefin cycle copolymer (COC) or a mixture thereof. COCs are produced by polymerization of cyclic monomers, such as norbornene with ethane, while COPs are produced by cyclic monomer ring opening metathesis followed by hydrogenation. COC, COP and COP / COC materials have a number of desirable characteristics, including high transparency, low density, excellent moisture barrier capabilities and resistance to aqueous and polar organic media. Specific examples include Topas® COC and Daikyo Crystal Zenith®.
[0071] Plastic bottles, cartridges and ampoules can be made from the plastic materials described above in relation to the plastic syringe cylinder, polyethylene (PP, for example, HDPE, LDPE), polyester, polyethylene terephthalate (PET), polyamides and their mixtures. It is also contemplated that plastic bottles, cartridges and ampoules have a multilayer structure with a layer in one of said materials and the other layer (s) made of one (or more) other materials.
[0072] According to the present invention, the "capping device" refers largely to any means for closing and sealing the distal open outlet end of a syringe. In the scope of the present invention, the term "open outlet end" or "distal open outlet end" refers to any open distal end of a syringe that is in fluid communication with the cylinder lumen. The cap device generally has a channel with a closed end and an open end, of a dimension to effectively receive and seal the open outlet end of the syringe, to prevent leakage.
[0073] In the case of a pre-filled plastic syringe without a pre-assembled needle, the cap device is a cap means commonly known as "tip cap". The tip cap forms a fluid-tight seal with the syringe tip to effectively close the syringe barrel and to prevent leakage of syringe barrel contents. The tip cap is usually removably attached to the tip of the syringe or to a luer ring. The luer ring surrounds the top of the syringe barrel (for example, the tip of the syringe). Preferably, the luer ring has internal threads, and the tip cap has external threads complementing said internal threads of said luer ring, for coupling the tip cap to the syringe cylinder. In the case of the pre-filled plastic syringe of the present invention, the luer collar is generally formed integrally (for example, molded unitarily with) the syringe cylinder. Before use, the tip can be removed, and a needle cannula (needle set) can then be firmly attached to the tip of the syringe.
[0074] In case the pre-filled syringe includes a cannula or needle cannula that is removable or non-removable (ie, permanent) (also called "needle" or "needle set") that extends from the tip of the syringe to administering the aqueous formulation of botulinum toxin from said syringe, the cap device may be called a "needle protector". Said needle protector generally has a channel with a closed end and an open end, having a dimension to receive and couple with the cannula (needle) mounted on the tip of the syringe. Typically, the (sharp) end of the cannula penetrates the closed end of the channel in the needle guard to seal the open end of the cannula.
[0075] The covering device (for example, tip cover or needle shield) can be a unitary member and usually manufactured from a flexible and resilient polymeric material (for example, an elastomer), or it can have an external cover made of a rigid plastic material that is coupled to a flexible or resilient inner material or cap that comprises, or is made of, for example, an elastomer, at least a portion of which contacts and seals the distal opening of the syringe. Generally, at least a portion of the outlet hitch that contacts the opening of the distal tip to form a fluid-tight seal is made from a flexible and / or resilient material (for example, an elastomer) and, when the engagement portion comes into contact with the aqueous botulinum toxin formulation during storage and / or use, is preferably made of a material with a minimized potential for undesirable extractables / leachables. In order to further decrease the amount of extractables and / or leachables and to increase compatibility with the aqueous botulinum toxin formulation, the outlet coupling portion may have a coating on it.
[0076] Suitable flexible and / or resilient materials of the cap device, particularly the portion that interconnects with the outlet, include elastomers that do not interfere with the aqueous formulation of botulinum toxin and that allow long-term storage. In particular, the part of the sealing system that comes into contact with, or is configured to come in contact with, the aqueous formulation of botulinum toxin (that is, the portion that interconnects with the outlet) must have low levels of extractables / leachables during prolonged storage of the aqueous botulinum toxin formulation. As used here, the term "elastomer" or "elastomeric material" refers primarily to crosslinked thermoset rubber polymers that are more easily deformable than plastics, but which are approved for use with pharmaceutical grade fluids and are not easily susceptible to leaching or gas migration.
[0077] Preferably, the elastomeric material suitable for use here in the present invention is selected from isoprene rubber (IS), butadiene rubber (polybutadiene, BR), butyl rubber (isobutylene and isoprene copolymer, IIR), rubber halogenated butyl (for example, butyl chlorinated rubber, CIIR; and butyl rubber with bromine: BIIR), styrene-butadiene rubber (styrene-butadiene copolymer, SBR) and mixtures thereof. Preferably, the elastomeric material is butyl rubber or a halogenated butyl rubber, particularly a butyl rubber with bromine or a butyl rubber with chlorine or a mixture thereof. The elastomeric material can also be reinforced with an inert mineral. In addition, it can be cured (for example, with organic peroxide, phenolic resins, etc.).
[0078] Suitable coatings that may optionally be present in the outlet hitch portion are made of, for example, the aforementioned elastomeric materials, are generally made of a material that does not undesirably interfere with the aqueous botulinum toxin formulation and has levels extractables / leachables. Coatings for use in the present invention include, but are not limited to, polypropylene, polyethylene, parylene (e.g., parylene N, parylene C and parylene HT) cross-linked silicone and, preferably, fluoropolymer coatings. Examples of suitable cross-linked silicone coating include B2 (Daikyo Seiko) or XSi ™ (Becton Dickinson) coating.
[0079] Fluoropolymer coatings include, but are limited to, fluorinated ethylene-propylene copolymers (e.g., tetrafluoroethylene-hexafluoropropylene (FEP) copolymer), fluorinated ethylene-ethylene copolymers (e.g., tetrafluoroethylene ethylene copolymer (e.g. ETFE), such as FluroTec®), PVA (a tetrafluoroethylene (TFE) copolymer and perfluoropropyl vinyl ether (PPVE)), tetrafluoroethylene-perfluorethylene copolymers, polyvinylidene fluoride (PVDF), polyvinyl fluoride (PVF), and polyvinyl (PVF) fluoride (PVF) mixtures thereof. Preferably, the coating is made of ETFE and, in particular, is a coating of FluroTec®.
[0080] With respect to the cartridge of the present invention, the distal end is sealed by a puncture membrane. The puncture membrane can be formed from a rubber or thin silicone, a plastic / thin polymer, a film like Mylar, a polyolefin like polyethylene or polypropylene, a metallic laminate like aluminum foil, etc. The membrane can be between about 0.001 and 2.0 mm, and generally between 0.002 mm and 0.65 mm thick. Likewise, the membrane can be made of an elastomeric material and optionally have a coating as described above, together with the pre-filled plastic syringe cap device.
[0081] With respect to the bottle of the present invention, the bottle closure system (e.g., cap), in particular those portions of the bottle closure system that come into contact with it, or that have the potential to come into contact with contact with and / or sealing the vial (for example, a septum) can be made of an elastomeric material, particularly a thermoplastic elastomeric material, and more particularly a styrenic block copolymer thermoplastic elastomer, or an elastomeric material, as described above, together with the pre-filled plastic syringe cap device of the present invention. Another suitable material is a silicone material. In addition, said materials may have an optional coating, in particular, a fluoropolymer coating, as defined above in connection with the pre-filled plastic syringe cap device.
[0082] According to the present invention, the pre-filled syringe generally includes a plunger rod assembly, which extends into the proximal end of the syringe cylinder. The plunger rod assembly may include a rod (also known as a thrust rod) with a plunger stopper at its tip (also known as a "plunger") in a sliding watertight engagement with the cylindrical wall of the cylinder lumen. The plunger forms the proximal seal and the dynamic seal that allows the extrusion of the liquid botulinum toxin formulation. The plunger stopper comes into contact with the aqueous botulinum toxin formulation during storage and / or administration. Therefore, the plunger stopper must be compatible with the aqueous formulation of botulinum toxin and not impair its long-term stability. In particular, the plunger stopper is preferably designed to minimize the amount of extractables / leachables after long-term storage.
[0083] In the present invention, the plunger stopper is preferably made of an elastomeric material, which optionally has a coating on at least a portion of the plunger stopper that comes into contact, or is capable of coming into contact , with the aqueous formulation of botulinum toxin during storage and / or use. Elastomeric plunger stoppers suitable for use in the present invention include, but are not limited to, isoprene rubber (IS), butadiene rubber (polybutadiene, BR), butyl rubber (isobutylene and isoprene copolymer, IIR), butyl rubber halogenated (for example, butyl rubber with chlorine, CIIR; and butyl rubber with bromine, BIIR), styrene-butadiene rubber (styrene-butadiene copolymer, SBR), and mixtures thereof. Preferably, the plunger stopper material is a butyl rubber or a halogenated butyl rubber, or a mixture thereof, particularly a butyl rubber with bromine or a butyl rubber with chlorine. The elastomeric material can also be reinforced with an inert mineral. In addition, it can be cured (for example, with organic peroxide, phenolic resins, etc.).
[0084] Preferably, the plunger stopper comprises a coating that acts as a barrier film. The coating is generally applied to at least the sealing surfaces, including the portion of the plunger stopper facing the cylinder lumen and which comes into contact with the aqueous botulinum toxin formulation during storage and / or use. The coating serves to provide good lubrication, minimizing the interaction between the plunger stopper and the liquid formulation of botulinum toxin.
[0085] The proper coatings of the plunger stopper are made of a material that does not interfere undesirably with the aqueous formulation of botulinum toxin and has low levels of extractables / leachables. Such coatings include, but are not limited to, polypropylene, polyethylene, parylene (e.g., parylene N, parylene C and parylene HT) cross-linked silicone and, preferably, flurpolymer coatings. Examples of suitable cross-linked silicone coating include B2 (Daikyo Seiko) or XSi ™ (Becton Dickinson) coating.
[0086] Fluoropolymer coatings include, but are limited to, fluorinated ethylene-propylene copolymers (e.g., tetrafluoroethylene-hexafluoropropylene (FEP) copolymer), fluorinated ethylene-ethylene copolymers (e.g., tetrafluoroethylene ethylene copolymer (e.g. ETFE), such as FluroTec®), PVA (a tetrafluoroethylene (TFE) copolymer and perfluoropropyl vinyl ether (PPVE)), tetrafluoroethylene-perfluorethylene copolymers, polyvinylidene fluoride (PVDF), polyvinyl fluoride (PVF), and polyvinyl (PVF) fluoride (PVF) mixtures thereof. Preferably, the coating is made of ETFE and, in particular, is a coating of FluroTec®.
[0087] The design of the plunger stopper is not particularly limited and can be a grouped ("nested") or upholstered ("bagged") stopper. In addition, the stem interface can be threaded to allow installation of the stem after sterilization. Alternatively, the stem interface can be created with a snap fit design. The stem, like the plunger stopper, is generally designed to withstand sterilization, but is not limited in any particular way. Typically, the rod is made of a plastic material such as a copolymer of ethylene-vinyl acetate (EVA) or polypropylene.
[0088] The rubber stopper of the cartridge of the present invention may comprise or be made of the same elastomeric materials, as described above, in relation to the plunger stopper of the plastic syringe. Likewise, the rubber stopper on the cartridge can have the same optional coating as defined above, in relation to the coating on the plunger stopper. In addition, the coating may be on at least a portion of the rubber stopper that comes into contact with the aqueous botulinum toxin formulation during storage and / or use.
[0089] Within the framework of the present invention, the pre-filled plastic syringe, including the cap device, syringe cylinder and plunger assembly before and after sterilization (for example, by gamma radiation, ethylene oxide or autoclaving) meet or exceed the standards for extractable substances as determined by The Japanese Pharmacopoeia, 14th Edition, No. 61, Test Methods for Plastic Containers (2001) as well as The Japanese Pharmacopoeia, 14th Edition, No. 59, Test for Rubber Closure for Aqueous Infusions. In addition, the polymer composition of the cover device and the plunger stopper after sterilization meet the combustion tests of No. 61 of The Japanese Pharmacopoeia, Test Methods for Plastic Containers (2001), as well as the acceptable limits for extractable substances as defined by the foaming test, pH test, potassium permanganate reducing substance test, UV spectrum test and evaporation test residue according to The Japanese Pharmacopoeia, No. 61, Test Methods for Plastic Containers (2001 ).
[0090] In another aspect, the present invention relates to a kit comprising a pre-loaded plastic container (for example, a syringe, vial, cartridge or ampoule), according to the present invention and, optionally, instructions of using said pre-loaded plastic container.
[0091] In a further aspect, the present invention relates to a pre-loaded plastic container (for example, a syringe, vial, cartridge or ampoule), according to the present invention, for use in therapy. In particular, the pre-loaded plastic container according to the present invention can be used in the treatment of a disease or condition caused by or associated with the hyperinic cholinergic innervation of the muscles or exocrine glands in a patient.
[0092] In the context of the present invention, if the container is not a syringe (for example, a vial, cartridge or ampoule), the content of these "non-syringe type" containers (i.e., the aqueous botulinum toxin formulation) is generally injected into the desired target site using a suitable injection device (for example, a syringe) in the same manner as described in this document in relation to the pre-filled plastic syringe. The cartridges are inserted into a cartridge injection device, as is known to those skilled in the art. The contents of vials and ampoules are usually aseptically filled into a syringe and then injected into the target site using a suitable injection device (for example, a syringe) in the same manner as described in this document for the syringe. preloaded plastic.
[0093] The term "cholinergic hyperactive innervation", as used here, refers to a synapse that is characterized by an unusually high amount of acetylcholine release in the synaptic cleft. "Abnormally high" refers to an increase, for example of up to 25%, up to 50% or more in relation to a reference activity that can be obtained, for example, comparing the release with the release in a synapse of the same type, but not in a hyperactive state, in which muscular dystonia can be indicative of the hyperactive state. "Up to 25%" means, for example, about 1% to about 25%. Methods for making the necessary measurements are known in the art.
[0094] Within the scope of the present invention, the disease or condition caused by or associated with the cholinergic hyperactive innervation of the muscles includes, but is not limited to, dystonias (e.g., blepharospasm, spasmodic torticollis, limb dystonia and specific task-type dystonias , such as clamp cramps), spasticity (for example, spasticity after stroke, spasticity caused by cerebral palsy), paratonia, dyskinesias (for example, tardive dyskinesia), focal spasms (for example, hemifacial spasm), cerebral palsy (juvenile ) (for example, spastic, dyskinetic or ataxic paralysis), strabismus, pain (for example, neuropathic pain), healing of wounds, tremors, tics and migraine.
[0095] The container preloaded with botulinum toxin (for example, a syringe, vial, cartridge or ampoule) of the present invention is particularly useful in the treatment of dystonia in a muscle. Exemplary dystonias include, but are not limited to, dystonias selected from the group consisting of (1) cranial dystonia, including blepharospasm and oromandibular dystonia of the type opening of the jaw or closing of the jaw, (2) cervical dystonia, including antecole, retrocol, laterocol and torticollis, (3) pharyngeal dystonia, (4) laryngeal dystonia, including spasmodic dysphonia, (5) dystonia of the limb, including arm dystonia, as specific task-type dystonias (eg, clamp cramp), leg dystonia, dystonia axial, segmental dystonia and (6) other dystonias.
[0096] The term "overactive exocrine gland", as used here, is not particularly limited and covers any exocrine gland with hyperactivity. It is anticipated, therefore, that the present invention can be applied to the treatment involving any of the glands mentioned in Sobotta, Johannes, Atlas der Anatomie des Menschen, 22. Edition, Volume 1 and 2, Urban & Fischer, 2005, which is incorporated herein by reference. Preferably, the hyperactive gland is an autonomic exocrine gland. The botulinum toxin composition is preferably injected into or near the overactive exocrine gland.
[0097] In the present invention, hyperactive exocrine glands include, but are not limited to, sweat gland, lacrimal gland, salivary glands and mucous glands. In addition, the overactive gland may also be associated with a disease or condition selected from the group consisting of Frey syndrome, crocodile tear syndrome, axillary hyperhidrosis, palmar hyperhidrosis, plantar hyperhidrosis, head and neck hyperhidrosis, body hyperhidrosis , rhinorrhea or relative hypersalivation in patients with stroke, Parkinson's disease or amyotrophic lateral sclerosis. In particular, the disease or condition caused by or associated with overactive cholinergic innervation of the exocrine glands may include drooling (hypersalivation, drooling) and excessive sweating (hyperhidrosis).
[0098] The administration is not limited to any administration regime, mode, form, dose and special interval. As is known to those skilled in the art, the amount or dose administered of botulinum toxin depends on the mode of application, the type of disease, the patient's weight, age, sex and health status, and which target tissues are chosen for injection. The botulinum toxin formulation is generally administered locally, for example, by subcutaneous or intramuscular injection into or near the target tissues (for example, muscles, skin and exocrine glands).
[0099] Different muscles, depending on their size, usually require a different dosage. A suitable dose can vary from 10 to 2,000 U, preferably from 50 to 500 U and, more preferably, from 100 to 350 U of botulinum toxin. For the treatment of exocrine glands, the dose is generally in the range of 10 to 500 U, preferably 20 to 200 U, and more preferably 30 to 100 U. These total amounts can be administered on the same day or on a subsequent day treatment. For example, during a first treatment session, a first fraction of the dose can be administered. During one or more treatment sessions, the remaining fraction of the total dose can be administered. In addition, the frequency of application is not particularly limited and suitable administration intervals can be three months or less (for example, 4 or 8 weeks) or more than three months.
[0100] In yet another aspect, the present invention relates to the use of the pre-loaded plastic container (for example, a syringe, vial, cartridge or ampoule) according to the present invention in cosmetic applications, such as for treatment of facial asymmetries and wrinkles / lines of the skin (for example, facial lines and facial wrinkles), such as upper facial rhythms, platysma bands, frontal glabellar lines, horizontal forehead lines, nasolabial folds, chin folds, "large" chin "," mental cessation ", puppet lines, buccal commissures, perioral wrinkles, crow's feet and jaw lines. Preferably, the container preloaded with botulinum toxin (for example, a syringe, vial, cartridge or ampoule) of the present invention is used for injection into the glabellar expression lines, crow's feet, perioral wrinkles and / or platysmal bands.
[0101] The amounts of botulinum toxin administered for cosmetic application are generally in the range of 1 to 5 U, 5 to 10 U, 10 to 20 U or 20 to 50 U. Such total amounts can be administered in the same day or in one day subsequent treatment. For example, during a first treatment session, a first fraction of the dose can be administered. This first fraction is preferably a suboptimal fraction, that is, a fraction that does not completely remove wrinkles or skin lines. During one or more treatment sessions, the remaining fraction of the total dose can be administered. Regarding more details of administration, the disclosure provided above regarding therapeutic use is referred to.
[0102] In still a further aspect, the present invention relates to a method of treating a disease or condition caused by or associated with the overactive cholinergic innervation of the muscles or exocrine glands in a patient, the method comprising administering an effective amount locally. botulinum toxin to a patient's muscle or exocrine gland using the pre-loaded plastic container (for example, a syringe, vial, cartridge or ampoule) according to the present invention.
[0103] The term "effective amount", as used here, refers to the amount of a botulinum toxin sufficient to effect beneficial or desired therapeutic, cosmetic or anesthetic results. The term "patient", as used herein, generally refers to a human being afflicted with a disease or condition caused by or associated with the overactive cholinergic innervation of the muscles or exocrine glands, or to a human being in need of cosmetic treatment or anesthetic. As used here, "patient" can be used interchangeably with "subject" or "individual".
[0104] The term "local administration", within the meaning of the present invention, preferably refers to subcutaneous or intramuscular injection into or near target tissues (for example, muscles, skin and exocrine glands). With respect to administration (for example, regimen, mode, form, dose and interval) and the disease or conditions to be treated, the same comments apply to those exposed above regarding the use of the glass container (for example, the syringe with botulinum toxin preloaded) for cosmetic and therapeutic applications.
[0105] In yet a further aspect, the present invention relates to a method for the cosmetic treatment of the skin, such as for the treatment of skin wrinkles and facial asymmetries, the method comprising administering locally an effective amount of botulinum toxin to a patient by intradermal, subdermal or subcutaneous injection, using the pre-filled plastic container (for example, a syringe, vial, cartridge or ampoule) according to the present invention.
[0106] Examples of cosmetic applications include those mentioned above. Regarding the meaning or definition of the terms "effective amount", "patient", the administration (for example, regimen, mode, form, dose and interval) and the disease or conditions to be treated, the comments provided above regarding to other aspects of the present invention apply in a similar manner, except where otherwise specified.
[0107] The present invention will now be further illustrated by the following non-limiting examples. Examples
[0108] The following examples show that, contrary to common expectation and belief in the technique, an aqueous formulation of botulinum toxin stored in a pre-filled syringe system exhibits excellent stability over an extended period of time (for example, during 9 to 12 months) at the refrigerator's standard temperature (2 to 8 ° C). In addition, extrapolation of the measured stability data indicates that the pre-filled botulinum toxin syringe is highly stable for at least 12 to 24 months at 2 to 8 ° C.
[0109] Consequently, the presentation of botulinum toxin can be changed from a lyophilized vial to a pre-filled plastic syringe format, which meets the demands of doctors and patients looking for easier, safer and more accurate modes of administration. Materials and methods
[0110] An aqueous formulation of botulinum liquid botulinum toxin was prepared by dissolving 1.0 mg of human serum albumin (HSA), 4.7 mg of sucrose and toxin IncobotulinumA in 0.9% saline to a concentration of 50 U / ml. The formulation was then filled into a plastic syringe cylinder with a luer-lock cap comprising a luer-lock and a tip cap which, when assembled, comes into contact with the opening of the distal tip of the syringe to seal the syringe barrel. Then, a plunger stopper was inserted into the proximal end portion of the cylinder to close the proximal opening. The resulting pre-filled plastic syringe was then stored at temperatures of 5 ° C or 25 ° C. Then, the stability of the aqueous botulinum toxin formulation at t = 0, 1, 3, 6, 9 and 12 months was assessed to determine the remaining toxin potency, pH value and subvisible particle count.
[0111] The toxin potency was determined using a mouse hemidiaphragm (HDA) assay according to Goschel et al. (Exp. Neurol. 147: 96 to 102, 1997). In summary, the assay was conducted by maintaining a murine nerve muscle preparation in an organ bath containing 4 ml of medium. The muscle was attached to a force transducer and electrically stimulated through the phrenic nerve, resulting in an isometric contraction force that remains constant for more than 180 min, if no toxins are added. After the introduction of the toxin into the organ bath, the amplitude of contraction of the nerve-stimulated muscle gradually declines. The amplitude of contraction of the diaphragm was monitored over time. As a reading, the time in which half of the initial contraction force is reached has been determined and is called the paralysis time. The increased time values, compared to initial values, reflect lower amounts of active toxin and loss of toxin potency, respectively.
[0112] pH measurements were carried out according to the standardized test method of Pharmacopoeia USP <791>, which describes the pH measurements for a multitude of pharmaceutical products, using a pH meter (Lab 870, Schott Instruments).
[0113] Particle measurements were performed using flow microscopy imaging (MFI) using a DPA-5200 particle analyzer system (ProteinSimple, Santa Clara, CA, USA) equipped with a 100 μm flow cell high resolution coated with silane. The samples were analyzed undiluted. The MFI View System (MVSS) software version 2-R2-6.1.20.1915 was used to perform the measurements, and the MFI View Analysis (MVAS) suite software, version 1.3.0.1007, was used to analyze the samples.
[0114] Two different systems of pre-filled plastic syringes (in the following "configurations A and B") have been studied, which differ from each other by the plunger stopper. Details of the examined syringe settings are summarized in Table 1. Table 1. Syringe settings A and B

1 = Gerresheimer 2 = siliconized with Dow Corning Medical Fluid 360 (viscosity 12,500 mm2 / s (12,500 cSt)) 3 = sterilized by gamma irradiation according to ISO 11137 Results
[0115] The results of the stability measures in terms of remaining toxin potency for configurations A and B are shown in Table 2 below. Table 2. Stability in terms of power
* the activity of the initial absolute toxin in units is in the range of 50 U to 54 U ** nd = not determined
[0116] As is evident from Table 2, the toxin essentially maintains its initial potency between 2 and 8 ° C over time, that is, there is essentially no loss of potency after storage for at least 18 months (one loss of power <10% after storage for 18 months). Even at room temperature (ie 25 ° C), stability is still acceptable, as indicated by a loss of power of not more than about 20% after 3 months.
[0117] An extrapolation of the stability data for configurations A and B between 2 and 8 ° C up to a storage time of 24 months is shown graphically in Figure 1. As can be seen, the maximum estimated loss of biological activity after 24 months should be around 10% and therefore be essentially the same as the loss of biological activity measured after 12 months.
[0118] In addition, pH measurements revealed that the pH value remained exceptionally stable over a period of up to 18 months. No trend towards higher or lower values was observed and all measured pH values remained within ± 0.4 of the initial pH (see Table 3). Table 3. Stability in terms of pH

[0119] In addition, particle size measurements by flow microscopy imaging showed a generally low number of particles and no significant increase in the number of particles (see Table 4). Table 4. Stability in terms of subvisible particle count

[0120] As can be seen from Table 4, the particle counts are well below 1,000 / mL and, in most cases, even below 250 / mL. Likewise, measurements of particles using the Resonant Mass Measurement (RMM) method of measurement (using the ARCHIMEDES particle methodology system, Affinity Biosensors, Santa Barbara, CA, USA) and the tracking analysis of nanoparticles (using a NanoSight LM20 system, NanoSight, Amesbury, UK) led to similar results and did not reveal significant particle counts.
[0121] In conclusion, the results presented above show that liquid formulations of botulinum toxin in pre-filled plastic syringes are stable for an extended storage time (for example, 12 to 24 months) at temperatures between 2 and 8 ° C. This finding was very surprising in view of the labile nature of botulinum toxin, which is known to be highly labile to heat and unstable at alkaline pH. This was even more surprising, since the concentrations of botulinum toxin in pre-filled syringes are exceptionally low and therefore the smallest absolute losses in the amount of active toxin will lead to large percentage changes.
[0122] Consequently, the above results show that botulinum toxin can be formulated in the shape of a pre-filled plastic syringe, which offers advantages over glass syringes in terms of tear resistance, weight reduction, greater flexibility for new forms of primary containers, improved dimensional tolerances and absence of undesirable substances (eg adhesives). In addition, compared to other botulinum toxin presentations, the pre-filled syringe format increases convenience and ease of handling, reduces medication errors, improves dosage accuracy, minimizes the risk of contamination, improves safety of sterility and increases security in administration.

权利要求:
Claims (14)
[0001]
1. Pre-filled plastic syringe characterized by the fact that it comprises an aqueous formulation of botulinum toxin, the plastic syringe comprising (a) a plastic syringe cylinder, which includes a proximal end and a distal end, and a cylindrical wall that extends between them and defines a lumen of the cylinder, the syringe cylinder having a tip that projects distally with a fluid passage that extends through it and communicates with the cylinder lumen, with the cylindrical wall having an inner surface optionally coated with a barrier layer, (b) a cap device with a portion that interconnects with the outlet, which seals and closes the end of the syringe's open distal outlet, the portion that connects with the outlet is made of an elastomeric material that, optionally, has a coating on its surface, and (c) a piston rod assembly that extends to the proximal end of the syringe cylinder and includes a plunger stopper in a sliding watertight engagement with the cylindrical wall of the cylinder lumen, the plunger stopper being made of an elastomeric material that optionally has a coating on at least a portion of the plunger stopper that comes into contact with the aqueous formulation of botulinum toxin during storage and / or injection, in which the elastomeric material of the portion that interconnects with the outlet is selected from isoprene rubber (IS), rubber butadiene (BR), butyl rubber, halogenated butyl rubber, styrene-butadiene rubber and mixtures thereof, and the elastomeric material of the plunger stopper is selected from isoprene rubber (IS), butadiene rubber (BR), butyl rubber, halogenated butyl rubber, styrene-butadiene rubber and mixtures thereof, and in which the activity of the toxin is not reduced by more than 25%, in relation to the initial activity of the toxin, after arm watering the pre-filled syringe for 12 months at 5 ° C, or for 3 months at 25 ° C.
[0002]
2. Pre-filled plastic syringe according to claim 1, characterized by the fact that the number of subvisible particles of size equal to or greater than 10 μm is below 1,000 / mL during storage for 6 to 24 months from 2 ° C to 25 ° C.
[0003]
3. Pre-filled plastic syringe according to claim 1 or 2, characterized by the fact that the pH value does not increase or decrease by more than 10% compared to the initial pH value, during the storage of the pre syringe - charged for 6 to 24 months from 2 ° C to 25 ° C, or where the pH of the aqueous botulinum toxin formulation during storage is maintained in the range of 6.1 to 7.3, or both conditions.
[0004]
4. Pre-filled plastic syringe according to any one of claims 1 to 3, characterized in that the botulinum toxin is present in the aqueous formulation at a concentration of 10 U / ml to 1,000 U / ml.
[0005]
5. Pre-filled plastic syringe according to any of claims 1 to 4, characterized in that the aqueous formulation of botulinum toxin in the pre-filled syringe does not contain a tampon.
[0006]
6. Pre-filled plastic syringe according to any one of claims 1 to 5, characterized in that the barrier layer of the syringe cylinder is present and is either a silicone-free layer or a silicone layer.
[0007]
7. Pre-filled plastic syringe according to any one of claims 1 to 6, characterized in that the coating on the portion that interconnects with the outlet is present and is a cross-linked silicone coating or a fluoropolymer coating.
[0008]
8. Pre-filled plastic syringe according to any one of claims 1 to 7, characterized in that the coating on the plunger stopper is present and is a cross-linked silicone coating or a fluoropolymer coating.
[0009]
9. Kit characterized by the fact that it comprises a pre-filled plastic syringe as defined in any one of claims 1 to 8 and, optionally, instructions for using said pre-filled plastic syringe.
[0010]
10. Pre-filled plastic syringe according to any one of claims 1 to 8, characterized in that it is for use in therapy.
[0011]
11. Pre-filled plastic syringe according to any one of claims 1 to 8, characterized in that it is for use in the treatment of a disease or condition caused by or associated with overactive cholinergic innervation of muscles or exocrine glands in a patient, including dystonia, spasticity, paratonia, dyskinesia, focal spasm, strabismus, pain, healing of wounds, tremors, tics, migraine, sialorrhea and hyperhidrosis.
[0012]
12. Use of the pre-filled plastic syringe, as defined in any of claims 1 to 8, characterized by the fact that it is for non-surgical cosmetic applications.
[0013]
13. Use according to claim 12, characterized in that the pre-filled plastic syringe as defined in any one of claims 1 to 8 is used for the treatment of skin wrinkles and facial asymmetries.
[0014]
14. Method for the cosmetic treatment of the skin, as for the treatment of skin wrinkles and facial asymmetries, the method characterized by the fact that it comprises administering an effective amount of botulinum toxin locally to a patient by intradermal, subdermal or subcutaneous injection, using the pre-filled plastic syringe as defined in any one of claims 1 to 8.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US11219717B2|2022-01-11|Botulinum toxin prefilled plastic syringe

---

US11167090B2|2021-11-09|Botulinum toxin prefilled container

---

RU2745739C2|2021-03-31|Syringe system pre-filled with botulinus toxin

---

US20220080127A1|2022-03-17|Botulinum toxin prefilled plastic syringe

同族专利:

---

公开号 | 公开日

---

AR103244A1|2017-04-26|

---

JP2021041173A|2021-03-18|

---

JP6813492B2|2021-01-13|

---

WO2016124213A1|2016-08-11|

---

TWI728964B|2021-06-01|

---

US11219717B2|2022-01-11|

---

SG11201706247VA|2017-08-30|

---

RU2017125279A3|2019-08-12|

---

TW201637641A|2016-11-01|

---

MX2017009380A|2018-01-09|

---

US20190336691A1|2019-11-07|

---

CN107206175B|2021-06-01|

---

IL253429D0|2017-09-28|

---

JP2018506351A|2018-03-08|

---

CN107206175A|2017-09-26|

---

AU2015381351A1|2017-08-03|

---

BR112017016759A2|2018-04-10|

---

IL253429A|2021-08-31|

---

US10406290B2|2019-09-10|

---

US20180015225A1|2018-01-18|

---

CA2974450A1|2016-08-11|

---

AU2015381351B2|2020-05-14|

---

RU2722290C2|2020-05-28|

---

EP3253364A1|2017-12-13|

---

RU2017125279A|2019-03-04|

---

KR20170109051A|2017-09-27|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US5607400A|1995-05-19|1997-03-04|Becton, Dickinson And Company|Pre-fillable syringe and stopper assembly therefor|

---

US20120238504A1|1998-09-11|2012-09-20|Solstice Neurosciences, Llc|Stable Formulations of Botulinum Toxin in Hydrogels|

---

TW574036B|1998-09-11|2004-02-01|Elan Pharm Inc|Stable liquid compositions of botulinum toxin|

---

US20060269575A1|2000-02-08|2006-11-30|Allergan, Inc.|Botulinum toxin pharmaceutical compositions formulated with recombinant albumin|

---

JP2003522154A|2000-02-08|2003-07-22|アラーガン、インコーポレイテッド|Botulinum toxin pharmaceutical composition|

---

DE10333317A1|2003-07-22|2005-02-17|Biotecon Therapeutics Gmbh|Formulation for protein medicines without the addition of human serum albumin |

---

US20080045889A1|2004-07-21|2008-02-21|Gerondale Scott J|Botoxo Needle Injector|

---

GB2416122A|2004-07-12|2006-01-18|Ipsen Ltd|Botulinum neurotoxin composition|

---

WO2006094263A2|2005-03-03|2006-09-08|Revance Therapeutics, Inc.|Compositions and methods for topical application and transdermal delivery of botulinum toxins|

---

CN101779949B|2005-03-09|2013-03-13|库蒂森斯股份公司|A three-dimensional adhesive device having a microelectronic system embedded therein|

---

JP2006314554A|2005-05-12|2006-11-24|Mitsubishi Pharma Corp|Package of syringe prefilled with heparin solution|

---

PL2032163T3|2006-06-15|2013-06-28|Novartis Ag|Adjuvant-sparing multi-dose influenza vaccination regimen|

---

GB0700523D0|2007-01-11|2007-02-21|Insense Ltd|The Stabilisation Of Proteins|

---

ES2520765T3|2007-02-15|2014-11-11|Allergan, Inc.|Use of botulinum toxin for the treatment of hyperhidrosis|

---

EP1997509A1|2007-06-01|2008-12-03|Merz Pharma GmbH & Co.KGaA|Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin|

---

CN101687018A|2007-06-01|2010-03-31|德国麦氏大药厂|Method based on neural malicious composition supply temperature-stable solid muscle relaxant of botulinum toxin|

---

WO2009003010A2|2007-06-25|2008-12-31|Becton, Dickinson And Company|Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution|

---

BRPI0813948B8|2007-07-10|2021-05-25|Medy Tox Inc|pharmaceutical liquid botulinum toxin composition with improved stability|

---

EP2048156A1|2007-10-12|2009-04-15|Merz Pharma GmbH & Co.KGaA|Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin|

---

US9107815B2|2008-02-22|2015-08-18|Allergan, Inc.|Sustained release poloxamer containing pharmaceutical compositions|

---

US8871807B2|2008-03-28|2014-10-28|Ecolab Usa Inc.|Detergents capable of cleaning, bleaching, sanitizing and/or disinfecting textiles including sulfoperoxycarboxylic acids|

---

US8809392B2|2008-03-28|2014-08-19|Ecolab Usa Inc.|Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents|

---

JP2011521744A|2008-05-30|2011-07-28|アラーガン、インコーポレイテッド|Injection device for injecting soft tissue enhancing fillers, bioactive agents and other biocompatible materials in liquid or gel form|

---

WO2010068467A1|2008-11-25|2010-06-17|Attenuex Technologies, Inc.|Implant with high vapor pressure medium|

---

CA2745657A1|2008-12-04|2010-08-26|Botulinum Toxin Research Associates, Inc.|Extended length botulinum toxin formulation for human or mammalian use|

---

US8535062B2|2008-12-23|2013-09-17|Simskin, Llc|Cutaneous surgical training model of the head, neck and shoulders|

---

BRPI1015938A2|2009-06-25|2016-09-27|Revance Therapeutics Inc|albumin-free botulinum toxin formulations|

---

CN106170582A|2012-07-03|2016-11-30|Sio2医药产品公司|The SiO of drug packagesxbarrier and coating process|

---

US10471212B2|2009-10-29|2019-11-12|W. L. Gore & Associates, Inc.|Silicone free drug delivery devices|

---

WO2011080543A1|2009-12-31|2011-07-07|Becton Dickinson France|Medical components having coated surfaces exhibiting low friction and/or low gas/liquid permeability|

---

US20130078295A1|2010-06-09|2013-03-28|Lipotec S.A.|Skin antiaging treatment|

---

EP2399601A1|2010-06-24|2011-12-28|Merz Pharma GmbH & Co. KGaA|Botulinum toxin therapy|

---

EP2619313B1|2010-09-26|2021-11-10|Da Yu Enterprises, L.L.C.|Method of recombinant macromolecular production|

---

FR2966044B1|2010-10-18|2012-11-02|Sanofi Pasteur|METHOD FOR CONDITIONING A VACCINE CONTAINING AN ALUMINUM ADJUVANT|

---

EP2776603B1|2011-11-11|2019-03-06|SiO2 Medical Products, Inc.|PASSIVATION, pH PROTECTIVE OR LUBRICITY COATING FOR PHARMACEUTICAL PACKAGE, COATING PROCESS AND APPARATUS|

---

US10780228B2|2012-05-07|2020-09-22|Medline Industries, Inc.|Prefilled container systems|

---

US20150297800A1|2012-07-03|2015-10-22|Sio2 Medical Products, Inc.|SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS|

---

US9133412B2|2012-07-09|2015-09-15|Tribofilm Research, Inc.|Activated gaseous species for improved lubrication|

---

US10894062B2|2012-08-10|2021-01-19|Aquavit Pharmaceuticals, Inc.|Vitamin supplement compositions for injection|

---

US10980865B2|2012-08-10|2021-04-20|Aquavit Pharmaceuticals, Inc.|Direct application system and method for the delivery of bioactive compositions and formulations|

---

WO2014052792A1|2012-09-28|2014-04-03|Sio2 Medical Products, Inc.|Halogenated or parylene polymer coating|

---

US20160015898A1|2013-03-01|2016-01-21|Sio2 Medical Products, Inc.|Plasma or cvd pre-treatment for lubricated pharmaceutical package, coating process and apparatus|

---

KR102167557B1|2013-03-11|2020-10-20|에스아이오2 메디컬 프로덕츠, 인크.|Coated Packaging|

---

US9937099B2|2013-03-11|2018-04-10|Sio2 Medical Products, Inc.|Trilayer coated pharmaceutical packaging with low oxygen transmission rate|

---

WO2014144926A1|2013-03-15|2014-09-18|Sio2 Medical Products, Inc.|Coating method|

---

DE102014101305A1|2014-02-03|2015-08-06|Heraeus Medical Gmbh|Device for storing and mixing bone cement|

---

CN106535858A|2014-03-26|2017-03-22|纳诺麦德皮肤护理公司|Plunger-like mass transportation device for dermal and transdermal delivery of a liquid or solid composition|

---

KR20170093780A|2014-09-02|2017-08-16|아메리칸 실버, 엘엘씨|Botulinum toxin and colloidal silver particles|

---

US20170238580A1|2014-11-11|2017-08-24|Pressed Juicery, LLC|System and process for destroying c. botulinum spores in pressed beverage using thermal pascalization|

---

TWI669129B|2014-12-23|2019-08-21|德商梅茲製藥有限兩合公司|Refilled glass container, a kit comprising the same and, a use thereof|

---

AU2015381351B2|2015-02-03|2020-05-14|Merz Pharma Gmbh & Co. Kgaa|Botulinum toxin prefilled container|

---

EP3294305A4|2015-05-15|2019-02-13|Carilion Clinic|Syringes and methods of using them to treat overactive bladder|

---

US9827282B2|2015-07-24|2017-11-28|Bao Tran|Medication dispensing system|

---

TWI737742B|2016-06-22|2021-09-01|德商梅茲製藥有限兩合公司|Botulinum toxin prefilled syringe system, kit having the same and use thereof|WO2006094263A2|2005-03-03|2006-09-08|Revance Therapeutics, Inc.|Compositions and methods for topical application and transdermal delivery of botulinum toxins|

---

US8168206B1|2005-10-06|2012-05-01|Allergan, Inc.|Animal protein-free pharmaceutical compositions|

---

US10792344B2|2006-06-29|2020-10-06|Merz Pharma Gmbh & Co. Kgaa|High frequency application of botulinum toxin therapy|

---

TWI669129B|2014-12-23|2019-08-21|德商梅茲製藥有限兩合公司|Refilled glass container, a kit comprising the same and, a use thereof|

---

AU2015381351B2|2015-02-03|2020-05-14|Merz Pharma Gmbh & Co. Kgaa|Botulinum toxin prefilled container|

---

TWI737742B|2016-06-22|2021-09-01|德商梅茲製藥有限兩合公司|Botulinum toxin prefilled syringe system, kit having the same and use thereof|

---

EP3863589A1|2018-10-08|2021-08-18|Merz Pharma GmbH & Co. KGaA|Neurotoxin prefilled vial|

---

CN113573727A|2019-02-21|2021-10-29|梅尔兹制药公司|New use of botulinum neurotoxin for the treatment of tremors|

---

US11054185B1|2020-02-24|2021-07-06|Lyophilization Technology, Inc.|Apparatus for lyophilization of products contained in product delivery units|

---

EP3875131A1|2020-03-06|2021-09-08|Schott AG|Pharmaceutical packaging receptacle with a lubricant layer for removal of a charge|

---

WO2021206360A1|2020-04-08|2021-10-14|메디톡스|Botulinum toxin pre-filled injectable formulation that facilitates discharge rate control and is stable|

法律状态:
2020-06-23| B15K| Others concerning applications: alteration of classification|Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/00 , A61K 38/48 , A61K 47/26 , A61Q 19/08 , A61M 5/31 Ipc: A61K 8/64 (2006.01), A61K 8/66 (2006.01), A61Q 19/ |

---

2020-06-23| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-11-24| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-01-12| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/12/2015, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP15000310|2015-02-03|

---

EP15000310.1|2015-02-03|

---

PCT/EP2015/002600|WO2016124213A1|2015-02-03|2015-12-22|Botulinum toxin prefilled container|

---